Federated Hermes
PTCT icon

Federated Hermes’s PTC Therapeutics PTCT Stock Holding History

Federated Hermes’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4M Buy
483,424
+257,508
+114% +$18.6M 0.06% 318
2026
Q1 		$15.4M Buy
225,916
+113,350
+101% +$8.03M 0.03% 531
2025
Q4 		$8.55M Buy
112,566
+97,750
+660% +$7.1M 0.01% 670
2025
Q3 		$909K Sell
14,816
-9,468
-39% -$493K ﹤0.01% 1171
2025
Q2 		$1.19M Sell
24,284
-51,061
-68% -$2.42M ﹤0.01% 1086
2025
Q1 		$3.84M Buy
75,345
+27,517
+58% +$1.37M 0.01% 777
2024
Q4 		$2.16M Buy
+47,828
New +$2.05M ﹤0.01% 912
2023
Q3 		– Sell
-732
Closed -$29.8K – 2180
2023
Q2 		$29.8K Sell
732
-7,265
-91% -$355K ﹤0.01% 1741
2023
Q1 		$387K Buy
+7,997
New +$366K ﹤0.01% 1464
2022
Q4 		– Sell
-72,477
Closed -$3.64M – 2252
2022
Q3 		$3.64M Buy
+72,477
New +$3.55M 0.01% 744
2021
Q2 		– Sell
-22
Closed -$1K – 2306
2021
Q1 		$1K Sell
22
-45,397
-100% -$2.7M ﹤0.01% 2185
2020
Q4 		$2.77M Buy
+45,419
New +$2.68M 0.01% 963
2020
Q2 		– Sell
-1,223
Closed -$55K – 2347
2020
Q1 		$55K Sell
1,223
-443,580
-100% -$22.3M ﹤0.01% 1702
2019
Q4 		$21.4M Buy
444,803
+433,141
+3,714% +$18.4M 0.05% 400
2019
Q3 		$394K Buy
+11,662
New +$508K ﹤0.01% 1487
2018
Q2 		– Sell
-29,457
Closed -$797K – 2270
2018
Q1 		$797K Buy
29,457
+28,452
+2,831% +$721K ﹤0.01% 1285
2017
Q4 		$17K Sell
1,005
-1,546
-61% -$26.2K ﹤0.01% 1798
2017
Q3 		$51K Sell
2,551
-1,534
-38% -$30K ﹤0.01% 1643
2017
Q2 		$75K Sell
4,085
-1,426
-26% -$19.2K ﹤0.01% 1614
2017
Q1 		$54K Buy
5,511
+4,538
+466% +$54.9K ﹤0.01% 1616
2016
Q4 		$11K Buy
973
+948
+3,792% +$9.95K ﹤0.01% 1824
2016
Q3 		$1K Sell
25
-16,843
-100% -$137K ﹤0.01% 2075
2016
Q2 		$118K Buy
+16,868
New +$124K ﹤0.01% 1547

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Federated Hermes's PTCT Position: Q2 2026 in Review

Federated Hermes increased its PTC Therapeutics (PTCT) stake by 114% in Q2 2026, buying an estimated $18.6M and bringing the position to 483,424 shares worth $39.4M. The position accounts for 0.06% of the portfolio, ranked #318.

Federated Hermes first reported a position in PTCT in Q2 2016 and has held it in 23 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Federated Hermes held 483,424 shares of PTC Therapeutics worth $39.4M as of Q2 2026.
  • Federated Hermes bought 257,508 PTC Therapeutics shares in Q2 2026, an estimated $18.6M.
  • PTC Therapeutics made up 0.06% of Federated Hermes's portfolio in Q2 2026, its #318 holding.
  • Federated Hermes first reported a position in PTC Therapeutics in Q2 2016 and has held it in 23 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.